Core Insights - Medera Inc. and its subsidiary Novoheart have installed the CTScreen™ platform at the University Medical Center Utrecht, enhancing capabilities in cardiac disease modeling and therapeutic development [1][2][3] Company Overview - Medera is a clinical-stage biopharmaceutical company focused on addressing difficult-to-treat diseases with significant unmet needs, utilizing next-generation gene and cell-based approaches [5] - Novoheart specializes in human-based cardiac tissue engineering, particularly through its "mini-Heart™" platform, which allows for accurate modeling of human-specific diseases [6] Technological Advancements - The CTScreen™ system supports high-throughput screening of bioengineered human cardiac tissues, enabling the evaluation of up to 96 samples simultaneously, which accelerates the drug development process [3][7] - This technology aims to improve the understanding of cardiac conditions and enhance the safety and efficacy of drug candidates [4][7] Research and Development Collaboration - The installation at UMC Utrecht signifies a strengthened partnership between Novoheart and the institution, with expectations for breakthroughs in cardiovascular research [4][7] - UMC Utrecht researchers will utilize the CTScreen™ platform to study disease mechanisms and optimize therapeutic candidates, particularly for conditions like familial cardiomyopathies [4][2] Clinical Development Pipeline - Medera's subsidiary Sardocor is advancing a pipeline of gene and cell therapies, with three ongoing clinical trials targeting heart failure and Duchenne Muscular Dystrophy-induced cardiomyopathy [9] - Sardocor has received FDA Investigational New Drug clearances for its therapies, indicating progress in clinical development [9]
Medera's Novoheart Expands Human Cardiac Research with CTScreen™ Installation at University Medical Center, Utrecht